Norman Tse
Directeur/Membre du Conseil chez Bio-Cancer Treatment International Ltd.
Profil
Norman Tse has held positions as a Director at Bio-Cancer Treatment International Ltd.
since 2019 and as a Vice President at Nan Fung Life Sciences since 2017.
Postes actifs de Norman Tse
| Sociétés | Poste | Début |
|---|---|---|
Nan Fung Life Sciences
 Nan Fung Life Sciences Investment ManagersFinance Nan Fung Life Sciences (Nan Fung Life Sciences) is a venture capital subsidiary of Vervain Group (Holdings) Ltd founded in 1954 by Vincent Cheung. The firm is headquartered in Hong Kong. | Analyste en capital-investissement | 01/10/2017 |
Bio-Cancer Treatment International Ltd.
 Bio-Cancer Treatment International Ltd. BiotechnologyHealth Technology Bio-Cancer Treatment International Ltd. is a Chinese company that focuses on researching and developing biological products and therapeutics for cancer and auto immune disorders. The company is based in Hong Kong, Hong Kong. The company was founded in 2000 by Jun Sing Lee and Paul Cheng, with Paul Cheng serving as the CEO since its inception. | Directeur/Membre du Conseil | 01/06/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Bio-Cancer Treatment International Ltd.
Bio-Cancer Treatment International Ltd. BiotechnologyHealth Technology Bio-Cancer Treatment International Ltd. is a Chinese company that focuses on researching and developing biological products and therapeutics for cancer and auto immune disorders. The company is based in Hong Kong, Hong Kong. The company was founded in 2000 by Jun Sing Lee and Paul Cheng, with Paul Cheng serving as the CEO since its inception. | Health Technology |
Nan Fung Life Sciences
Nan Fung Life Sciences Investment ManagersFinance Nan Fung Life Sciences (Nan Fung Life Sciences) is a venture capital subsidiary of Vervain Group (Holdings) Ltd founded in 1954 by Vincent Cheung. The firm is headquartered in Hong Kong. | Finance |
